Avyxa

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Feb 13, 2026FDAVePesid — AVOPEF

Aug 8, 2025FDAParaplatin — KYXATA

Oct 23, 2024FDATaxotere — BEIZRAY

Nov 22, 2022FDATaxotere — DOCIVYX

Nov 21, 2017FDAAloxi — PALONOSETRON HYDROCHLORIDE

Aug 22, 2016FDAAloxi — PALONOSETRON HYDROCHLORIDE

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

TaxotereAug 7, 2031 Taxotere3 patentsSep 30, 2033 Taxotere4 patentsMar 14, 2036 ParaplatinApr 1, 2045

Regulatory

Regulatory Timeline

19981 event

FDAFeb 27

VePesid — ETOPOPHOS PRESERVATIVE FREE

Application NDA020906 (NDA)

20031 event

FDAJul 14

Paraplatin — PARAPLATIN

Application NDA020452 (NDA)

20082 events

FDAAug 22

Aloxi — ALOXI

Application NDA022233 (NDA)

FDAFeb 29

Aloxi — ALOXI

Application NDA021372 (NDA)

20101 event

FDAAug 3

Taxotere — TAXOTERE

Application NDA020449 (NDA)

20114 events

FDAJun 29

Taxotere — DOCETAXEL

Application NDA201525 (NDA)

FDAJun 8

Taxotere — DOCETAXEL

Application NDA201195 (NDA)

FDAMay 3

Taxotere — DOCEFREZ

Application NDA022534 (NDA)

FDAMar 8

Taxotere — DOCETAXEL

Application NDA022234 (NDA)

20121 event

FDAJan 11

Taxotere — DOCETAXEL

Application NDA022312 (NDA)

20131 event

FDAApr 12

Taxotere — DOCETAXEL

Application NDA203551 (NDA)

20141 event

FDAMar 13

Taxotere — DOCETAXEL

Application NDA202356 (NDA)

20151 event

FDADec 22

Taxotere — DOCETAXEL

Application NDA205934 (NDA)

20162 events

FDAAug 22

Aloxi — PALONOSETRON HYDROCHLORIDE

Application NDA207963 (NDA)

FDAMar 1

Aloxi — POSFREA

Application NDA203050 (NDA)

20171 event

FDANov 21

Aloxi — PALONOSETRON HYDROCHLORIDE

Application NDA208109 (NDA)

20221 event

FDANov 22

Taxotere — DOCIVYX

Application NDA215813 (NDA)

20241 event

FDAOct 23

Taxotere — BEIZRAY

Application NDA218711 (NDA)

20251 event

FDAAug 8

Paraplatin — KYXATA

Application NDA219921 (NDA)

20261 event

FDAFeb 13

VePesid — AVOPEF

Application NDA220200 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)